Fundraising Fox
/Companies
Sign in

Secretome Therapeutics

Dallas, US · Founded 2018 · Delaware corporation · 1 known investors

Find your way into Secretome Therapeutics

Sign up to find every way you can get introduced to Secretome Therapeutics

  • Your email: who you already know at Secretome Therapeutics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Secretome Therapeutics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Secretome Therapeutics develops cell-based and secretome therapies derived from neonatal cardiac progenitor cells (nCPCs) for patients with rare and serious cardiac diseases. Its early-stage pipeline targets heart failure with preserved ejection fraction and dilated cardiomyopathy.

BiotechHealthtech

Founders & leadership

AS
ANGELA SHENNamed on SEC filing
HR
HENRIK RASMUSSENNamed on SEC filing
VJ
VINEET JINDALNamed on SEC filing
SK
SUNJAY KAUSHALNamed on SEC filing
WN
WILLIAM NILANDNamed on SEC filing

Investors · 1

Funding

SEC filings, press & company announcements

$36.9M disclosed across 2 of 4 rounds · 2022–2026

▶$6.9MraisedFeb 2023 · 48 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • ANGELA SHENDirector
  • HENRIK RASMUSSENDirector
  • VINEET JINDALExecutive Officer, Director
  • SUNJAY KAUSHALDirector
  • WILLIAM NILANDDirector
Offering amount
$10.9M
Amount sold
$6.9M
Minimum investment
$1
First sale
Nov 2022
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Secretome Therapeutics Expands Rare Disease Leadership Team - BioSpacebiospace.com · Jul 2026Secretome Therapeutics Raises $30M in Series A Fundingfinsmes.com · May 2026Secretome Therapeutics Announces $30 Million Series A Financing From RA Capital Management to Advance STM-01 for Duchenne-Associated Cardiomyopathyfinance.yahoo.com · May 2026Secretome Therapeutics Raises $20.4M in Financingfinsmes.com · Nov 2024

Frequently asked questions

What does Secretome Therapeutics do?
Secretome Therapeutics develops cell-based and secretome therapies derived from neonatal cardiac progenitor cells (nCPCs) for patients with rare and serious cardiac diseases. Its early-stage pipeline targets heart failure with preserved ejection fraction and dilated cardiomyopathy.
Who are Secretome Therapeutics's investors?
Secretome Therapeutics's investors include RA Capital.
How much funding has Secretome Therapeutics raised?
Secretome Therapeutics has disclosed $36.9M raised across 2 of its 4 known rounds.
Where is Secretome Therapeutics headquartered?
Secretome Therapeutics is headquartered in Dallas, US.